Developer docs
API playgroundTry for free, no card

Search company profiles

TNC Bio

Full company profile

uuid022bd3i

Namestring
TNC Bio
Legal namestring
TNC Bio BV
Websiteurl
tncbio.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

TNC Bio BV is a privately-held Dutch biotechnology company headquartered at High Tech Campus 29 in Eindhoven, Netherlands, founded in 2011. The company develops and manufactures chemically defined, animal component-free (ACF) cell culture supplements and media used primarily in viral vaccine production, cell therapy manufacturing, and life science research. The product portfolio is anchored by XerumFree™ (XF212), a fully defined serum replacement based on recombinant proteins produced via ACF bacterial processes; CHOiX™, a defined medium for CHO cell bioprocess applications; XF ViPro, a 2025-launched supplement for Vero-cell-based virus production; and the XF Cell Growth Kit family covering endothelial cells, mesenchymal stem cells, and keratinocytes for research-grade use.

The company's core technology rests on fully characterized synthetic and recombinant formulations that eliminate reliance on fetal bovine serum (FBS). Key claimed differentiators include batch-to-batch consistency, full traceability, ultra-low protein content, and supply chain stability derived from raw materials that are not sensitive to world market volatility. The technical positioning directly addresses mounting regulatory pressure across the vaccine and cell therapy industries to remove animal-derived components from production processes due to virus and prion contamination risk.

TNC Bio operates a hybrid go-to-market model: direct B2B sales handle production-scale and custom-volume orders, while a global authorized distributor network covers R&D and routine commercial sales. The distributor footprint spans 35+ countries across Europe, Asia-Pacific, North America, and the Middle East & Africa, with named channel partners including Fisher Scientific, Amsbio, CliniSciences, Westburg, Funakoshi, Caldic, and Stratech. Customer segments are organized horizontally across vaccine producers, cell therapy developers, and life science research institutions, with packaging tailored to both R&D (100/500 ml bottles) and production-scale (bags, vessels) requirements.

Short descriptiontext

TNC Bio BV is a Dutch biotechnology company that develops and manufactures chemically defined, animal component-free cell culture supplements and media — including XerumFree, CHOiX, and XF ViPro — serving vaccine producers, cell therapy developers, and research institutions globally through a distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell culture media, animal-free supplements, vaccine production, cell therapy reagents, bioprocess solutions
Industry1 code
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Culture Media & Supplements
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Culture Media and Supplements
TypeOne Time License
Description

TNC Bio generates revenue through the sale of chemically defined cell culture supplements and media products including XerumFree, CHOiX, XF ViPro, and various cell growth kits. Products are sold in standard packaging (100ml, 500ml bottles) for R&D and in larger volumes for production purposes.

tncbio.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1XerumFree
Description

A fully defined additive for serum-free cell culture, avoiding lot-to-lot variations. Chemically defined supplement for a wide range of cell culture practices.

tncbio.com
+3 more records
Core offering1 text field

TNC Bio manufactures and supplies chemically defined, animal component-free (ACF) cell culture supplements and media products for vaccine production, cell therapy development, and life science research. Its product portfolio includes the XerumFree™ serum replacement, CHOiX™ medium for CHO cells, XF ViPro for virus production with Vero cells, and XF Cell Growth Kits for endothelial cells, mesenchymal stem cells, and keratinocytes. Products are sold in standard packaging for R&D and in custom volumes (bags or vessels) for production-scale bioprocess applications through a global authorized distributor network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Cell output comparable or higher compared to FBS or other undefined media in production environments
Product overview1 text field

TNC Bio offers a portfolio of chemically defined, animal component-free (ACF) cell culture products centered around three core product lines: XerumFree™ serves as the foundational fully defined serum replacement applicable across broad cell culture applications; CHOiX™ provides a specialized fully defined medium optimized for CHO cell bioprocess production of recombinant proteins; and the XF Cell Growth Kit family includes targeted solutions for specific cell types including endothelial cells (XF501), mesenchymal stem cells (MSC505), and keratinocytes (XF-K-500). The most recent addition to the portfolio is XF ViPro, a chemically defined supplement designed for virus production applications with Vero cells. All products share the common value proposition of eliminating animal-derived materials, ensuring batch-to-batch consistency, and enabling more efficient downstream processing compared to traditional serum-based media.

Product and service6 records
1XerumFree™ (XF212)
CategorySerum Replacement Supplement
Description

A fully defined additive for serum-free cell culture that avoids lot-to-lot variations. All components are highly purified, identified chemical compounds of synthetic or recombinant origin, with ultra-low protein content and proteins derived solely from a recombinant bacterial process in ACF media. Used in viral vaccine production, cell therapy, and other serum-free cell culture applications.

2XF ViPro Medium Supplement
CategoryVirus Production Medium Supplement
Description

A chemically defined, animal/human compound free medium supplement designed for use with Vero cells and other cell lines in virus production applications. Eliminates reliance on animal-derived components, enhances batch-to-batch consistency, and reduces downstream processing time. Can be added to any basal medium for flexibility.

3CHOiX™
CategoryCHO Cell Culture Medium
Description

A fully defined and animal/human component free medium for optimal cell growth and expression of CHO cells, applicable in both R&D projects and manufacturing. The balanced formulation facilitates optimal and high density cell growth as well as high viability of the cells.

4XF501 Defined Endothelial Cell Growth Kit
CategoryEndothelial Cell Growth Kit
Description

A complete medium for optimal growth of endothelial cells from large vessels. Contains essential and non-essential amino acids, vitamins, organic and inorganic compounds, plus an optimized combination of growth factors, hormones and a growth supplement. All components are free of animal and/or human derived materials. For in vitro research applications only.

5MSC505 Mesenchymal Stem Cell Growth Kit
CategoryStem Cell Growth Kit
Description

A serum-free mesenchymal stem cell growth kit providing a complete medium for growth of mesenchymal stem cells isolated from bone marrow, cord blood, peripheral blood, fetal liver, lung and adipose tissue. Consists of a basal medium and a supplement. All components are free of animal derived materials. For in vitro research applications only.

6XF-K-500 Keratinocyte Growth Medium Kit
CategoryKeratinocyte Growth Medium
Description

A chemically defined, low calcium (0.07 mM) medium formulated for optimal growth of human primary keratinocytes. Contains essential and non-essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors, and trace minerals. For research use only.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

European distributor for XerumFree and other TNC Bio products across multiple European countries.

Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

European distributor for XerumFree products, serving customers across Europe and Africa.

Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for XerumFree in United Kingdom and United States markets.

Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Benelux distributor for TNC Bio cell culture products.

5Funakoshi
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Japanese distributor for TNC Bio products including XerumFree.

tncbio.com
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Italy and Switzerland for TNC Bio products.

Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

UK-based distribution partner for TNC Bio products.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provider of serum-free media and primary cell culture kits (including mesenchymal stem cell and endothelial cell products) that overlap with TNC Bio's XF Cell Growth Kits portfolio in the research and cell therapy supply market.

TypeEmerging player
Description

Supplies defined media, cytokines, and growth factors for cell therapy and regenerative medicine research; offers alternative substitute inputs that could compete with TNC Bio's growth kits and supplements in customer formulation decisions.

3Corning Life Sciences
TypeDirect peer
Description

Corning offers defined and serum-free cell culture media (and vessels) targeting bioprocess and cell therapy customers; directly comparable in addressing ACF manufacturing needs alongside TNC Bio.

4Merck KGaA / Sigma-Aldrich (Life Science)
TypeBroad incumbent
Description

Sigma-Aldrich/Merck supplies a broad range of cell culture media and reagents, including serum-free and defined formulations; directly competitive with TNC Bio's media portfolio in research and bioproduction.

TypeBroad incumbent
Description

Gibco cell culture media is the dominant brand in research and production-scale media for vaccine, cell therapy, and recombinant protein workflows; TNC Bio's ACF portfolio directly overlaps the same customer pain points around FBS elimination and batch consistency.

TypeBroad incumbent
Description

Cytiva's HyClone media business supplies serum-free and chemically defined media for vaccine and biopharmaceutical production; competes head-on with TNC Bio's XerumFree and CHOiX product lines in the bioprocess media category.

TypeDirect peer
Description

Specialist supplier of GMP-grade raw materials and media for cell and gene therapy manufacturing; peer in the niche of defined, animal-component-free ancillary materials serving cell therapy producers targeted by TNC Bio.

TypeBroad incumbent
Description

Bioprocess supplier offering upstream media, buffers, and process solutions serving vaccine and cell therapy manufacturers; competes with TNC Bio in defined, animal-free media for production environments.

TypeBroad incumbent
Description

Global bioprocess leader offering cell culture media and manufacturing services for vaccines, recombinant proteins, and cell therapies; directly comparable to TNC Bio's ACF media offerings but at vastly larger scale and portfolio breadth.

TypeDirect peer
Description

Specialist in cell culture media and supplements for cell therapy, gene therapy, and reproductive medicine; comparable ACF and serum-free solutions targeting overlapping biopharma customers to TNC Bio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TNC Bio

Cell Culture Media & Supplementstncbio.com

TNC Bio BV is a Dutch biotechnology company that develops and manufactures chemically defined, animal component-free cell culture supplements and media — including XerumFree, CHOiX, and XF ViPro — serving vaccine producers, cell therapy developers, and research institutions globally through a distributor network.

What TNC Bio does

TNC Bio BV is a privately-held Dutch biotechnology company headquartered at High Tech Campus 29 in Eindhoven, Netherlands, founded in 2011. The company develops and manufactures chemically defined, animal component-free (ACF) cell culture supplements and media used primarily in viral vaccine production, cell therapy manufacturing, and life science research. The product portfolio is anchored by XerumFree™ (XF212), a fully defined serum replacement based on recombinant proteins produced via ACF bacterial processes; CHOiX™, a defined medium for CHO cell bioprocess applications; XF ViPro, a 2025-launched supplement for Vero-cell-based virus production; and the XF Cell Growth Kit family covering endothelial cells, mesenchymal stem cells, and keratinocytes for research-grade use.

The company's core technology rests on fully characterized synthetic and recombinant formulations that eliminate reliance on fetal bovine serum (FBS). Key claimed differentiators include batch-to-batch consistency, full traceability, ultra-low protein content, and supply chain stability derived from raw materials that are not sensitive to world market volatility. The technical positioning directly addresses mounting regulatory pressure across the vaccine and cell therapy industries to remove animal-derived components from production processes due to virus and prion contamination risk.

TNC Bio operates a hybrid go-to-market model: direct B2B sales handle production-scale and custom-volume orders, while a global authorized distributor network covers R&D and routine commercial sales. The distributor footprint spans 35+ countries across Europe, Asia-Pacific, North America, and the Middle East & Africa, with named channel partners including Fisher Scientific, Amsbio, CliniSciences, Westburg, Funakoshi, Caldic, and Stratech. Customer segments are organized horizontally across vaccine producers, cell therapy developers, and life science research institutions, with packaging tailored to both R&D (100/500 ml bottles) and production-scale (bags, vessels) requirements.

TNC Bio firmographics

Firmographics
Name
TNC Bio
Legal name
TNC Bio BV
Website
https://tncbio.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
TNC Bio BV is a Dutch biotechnology company that develops and manufactures chemically defined, animal component-free cell culture supplements and media — including XerumFree, CHOiX, and XF ViPro — serving vaccine producers, cell therapy developers, and research institutions globally through a distributor network.
Ownership category
akta.pro rank

TNC Bio industry classification

Industry
Product category
Cell Culture Media & Supplements
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell culture media
  • Animal-free supplements
  • Vaccine production
  • Cell therapy reagents
  • Bioprocess solutions

Where TNC Bio is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

TNC Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Cell Culture Media and Supplements: TNC Bio generates revenue through the sale of chemically defined cell culture supplements and media products including XerumFree, CHOiX, XF ViPro, and various cell growth kits. Products are sold in standard packaging (100ml, 500ml bottles) for R&D and in larger volumes for production purposes.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

TNC Bio product offering

Product offering

Core offering

TNC Bio manufactures and supplies chemically defined, animal component-free (ACF) cell culture supplements and media products for vaccine production, cell therapy development, and life science research. Its product portfolio includes the XerumFree™ serum replacement, CHOiX™ medium for CHO cells, XF ViPro for virus production with Vero cells, and XF Cell Growth Kits for endothelial cells, mesenchymal stem cells, and keratinocytes. Products are sold in standard packaging for R&D and in custom volumes (bags or vessels) for production-scale bioprocess applications through a global authorized distributor network.

Product overview

TNC Bio offers a portfolio of chemically defined, animal component-free (ACF) cell culture products centered around three core product lines: XerumFree™ serves as the foundational fully defined serum replacement applicable across broad cell culture applications; CHOiX™ provides a specialized fully defined medium optimized for CHO cell bioprocess production of recombinant proteins; and the XF Cell Growth Kit family includes targeted solutions for specific cell types including endothelial cells (XF501), mesenchymal stem cells (MSC505), and keratinocytes (XF-K-500). The most recent addition to the portfolio is XF ViPro, a chemically defined supplement designed for virus production applications with Vero cells. All products share the common value proposition of eliminating animal-derived materials, ensuring batch-to-batch consistency, and enabling more efficient downstream processing compared to traditional serum-based media.

Differentiator

Problem solved

Functional benefit

Brands

  • XerumFree: A fully defined additive for serum-free cell culture, avoiding lot-to-lot variations. Chemically defined supplement for a wide range of cell culture practices.
  • CHOiX
  • XF ViPro
  • XF Cell Growth Kits

Products and services

  • XerumFree™ (XF212) A fully defined additive for serum-free cell culture that avoids lot-to-lot variations. All components are highly purified, identified chemical compounds of synthetic or recombinant origin, with ultra-low protein content and proteins derived solely from a recombinant bacterial process in ACF media. Used in viral vaccine production, cell therapy, and other serum-free cell culture applications.
  • XF ViPro Medium Supplement A chemically defined, animal/human compound free medium supplement designed for use with Vero cells and other cell lines in virus production applications. Eliminates reliance on animal-derived components, enhances batch-to-batch consistency, and reduces downstream processing time. Can be added to any basal medium for flexibility.
  • CHOiX™ A fully defined and animal/human component free medium for optimal cell growth and expression of CHO cells, applicable in both R&D projects and manufacturing. The balanced formulation facilitates optimal and high density cell growth as well as high viability of the cells.
  • XF501 Defined Endothelial Cell Growth Kit A complete medium for optimal growth of endothelial cells from large vessels. Contains essential and non-essential amino acids, vitamins, organic and inorganic compounds, plus an optimized combination of growth factors, hormones and a growth supplement. All components are free of animal and/or human derived materials. For in vitro research applications only.
  • MSC505 Mesenchymal Stem Cell Growth Kit A serum-free mesenchymal stem cell growth kit providing a complete medium for growth of mesenchymal stem cells isolated from bone marrow, cord blood, peripheral blood, fetal liver, lung and adipose tissue. Consists of a basal medium and a supplement. All components are free of animal derived materials. For in vitro research applications only.
  • XF-K-500 Keratinocyte Growth Medium Kit A chemically defined, low calcium (0.07 mM) medium formulated for optimal growth of human primary keratinocytes. Contains essential and non-essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors, and trace minerals. For research use only.

Quantifiable outcome

  • Cell output comparable or higher compared to FBS or other undefined media in production environments

Companies that use TNC Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

TNC Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TNC Bio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered standard.

  • CliniSciencesstandardChannel Partner/ Reseller/ DistributorEuropean distributor for XerumFree and other TNC Bio products across multiple European countries.
  • Fisher ScientificstandardChannel Partner/ Reseller/ DistributorEuropean distributor for XerumFree products, serving customers across Europe and Africa.
  • Amsbio Ltd (UK) and Amsbio LLC (USA)standardChannel Partner/ Reseller/ DistributorDistribution partner for XerumFree in United Kingdom and United States markets.
  • WestburgstandardChannel Partner/ Reseller/ DistributorBenelux distributor for TNC Bio cell culture products.
  • FunakoshistandardChannel Partner/ Reseller/ DistributorJapanese distributor for TNC Bio products including XerumFree.
  • CaldicstandardChannel Partner/ Reseller/ DistributorDistribution partner in Italy and Switzerland for TNC Bio products.
  • StratechstandardChannel Partner/ Reseller/ DistributorUK-based distribution partner for TNC Bio products.

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

TNC Bio competitors and assessment

Company assessment

Direct peers

  • STEMCELL Technologies: Provider of serum-free media and primary cell culture kits (including mesenchymal stem cell and endothelial cell products) that overlap with TNC Bio's XF Cell Growth Kits portfolio in the research and cell therapy supply market.
  • Corning Life Sciences: Corning offers defined and serum-free cell culture media (and vessels) targeting bioprocess and cell therapy customers; directly comparable in addressing ACF manufacturing needs alongside TNC Bio.
  • CellGenix: Specialist supplier of GMP-grade raw materials and media for cell and gene therapy manufacturing; peer in the niche of defined, animal-component-free ancillary materials serving cell therapy producers targeted by TNC Bio.
  • FUJIFILM Irvine Scientific: Specialist in cell culture media and supplements for cell therapy, gene therapy, and reproductive medicine; comparable ACF and serum-free solutions targeting overlapping biopharma customers to TNC Bio.

Emerging players

  • Bio-Techne (R&D Systems): Supplies defined media, cytokines, and growth factors for cell therapy and regenerative medicine research; offers alternative substitute inputs that could compete with TNC Bio's growth kits and supplements in customer formulation decisions.

Broad incumbents

  • Merck KGaA / Sigma-Aldrich (Life Science): Sigma-Aldrich/Merck supplies a broad range of cell culture media and reagents, including serum-free and defined formulations; directly competitive with TNC Bio's media portfolio in research and bioproduction.
  • Thermo Fisher Scientific (Gibco): Gibco cell culture media is the dominant brand in research and production-scale media for vaccine, cell therapy, and recombinant protein workflows; TNC Bio's ACF portfolio directly overlaps the same customer pain points around FBS elimination and batch consistency.
  • Cytiva (HyClone): Cytiva's HyClone media business supplies serum-free and chemically defined media for vaccine and biopharmaceutical production; competes head-on with TNC Bio's XerumFree and CHOiX product lines in the bioprocess media category.
  • Sartorius (BIA Separations / Cell Culture Media): Bioprocess supplier offering upstream media, buffers, and process solutions serving vaccine and cell therapy manufacturers; competes with TNC Bio in defined, animal-free media for production environments.
  • Lonza Group: Global bioprocess leader offering cell culture media and manufacturing services for vaccines, recombinant proteins, and cell therapies; directly comparable to TNC Bio's ACF media offerings but at vastly larger scale and portfolio breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

TNC Bio social profiles

Digital presence

TNC Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TNC Bio leadership team

Management profile

Number of profiles

TNC Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TNC Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TNC Bio

What does TNC Bio do?

TNC Bio manufactures and supplies chemically defined, animal component-free (ACF) cell culture supplements and media products for vaccine production, cell therapy development, and life science research. Its product portfolio includes the XerumFree™ serum replacement, CHOiX™ medium for CHO cells, XF ViPro for virus production with Vero cells, and XF Cell Growth Kits for endothelial cells, mesenchymal stem cells, and keratinocytes. Products are sold in standard packaging for R&D and in custom volumes (bags or vessels) for production-scale bioprocess applications through a global authorized distributor network.

Is TNC Bio a public or private company?

TNC Bio is a private company. It is classified as unknown and is currently operating.

When was TNC Bio founded?

TNC Bio was founded in 2011. It employs 1 to 10 people.

Where is TNC Bio based?

TNC Bio is headquartered in Eindhoven, Netherlands, in the Europe region.

How does TNC Bio make money?

One revenue line is on record: cell Culture Media and Supplements.

Who are TNC Bio's main competitors?

Direct peers on record are STEMCELL Technologies, Corning Life Sciences, CellGenix and FUJIFILM Irvine Scientific. Bio-Techne (R&D Systems) is listed as an emerging player. Broad incumbents are Merck KGaA / Sigma-Aldrich (Life Science), Thermo Fisher Scientific (Gibco), Cytiva (HyClone), Sartorius (BIA Separations / Cell Culture Media) and Lonza Group.

Does TNC Bio have an API?

No public API is recorded for TNC Bio.

What industry is TNC Bio in?

TNC Bio's product category is Cell Culture Media & Supplements. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales